Sanofi
A global biopharmaceutical company that discovers, develops, and markets medicines and vaccines.
SAN | PA
Overview
Corporate Details
- ISIN(s):
- FR0000120578 (+39 more)
- LEI:
- 549300E9PC51EN656011
- Country:
- France
- Address:
- 46 AVENUE DE LA GRANDE ARMEE, 75017 PARIS
- Sector:
- Manufacturing
Description
Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-10-09 07:00 |
Communiqué de presse : De nouvelles données sur le Beyfortus présentées à l’IDW…
|
French | 214.3 KB | ||
| 2024-10-09 07:00 |
Press Release: New Beyfortus data featured at IDWeek reinforce real-world effec…
|
English | 206.1 KB | ||
| 2024-10-02 17:06 |
6-K
|
English | 60.7 KB | ||
| 2024-09-27 15:35 |
Communiqué de presse : Dupixent est le premier médicament biologique approuvé a…
|
French | 299.7 KB | ||
| 2024-09-27 15:35 |
Press Release: Dupixent approved in the US as the first-ever biologic medicine …
|
English | 278.2 KB | ||
| 2024-09-27 13:00 |
Communiqué de presse : Dupixent, premier médicament biologique approuvé en Chin…
|
French | 284.5 KB | ||
| 2024-09-27 13:00 |
Press Release: Dupixent approved in China as the first-ever biologic medicine f…
|
English | 267.4 KB | ||
| 2024-09-26 07:30 |
Communiqué de presse : Mise en ligne du document «Q3 2024 Aide mémoire »
|
French | 139.5 KB | ||
| 2024-09-26 07:30 |
Press Release: Availability of the Q3 2024 Aide mémoire
|
English | 136.7 KB | ||
| 2024-09-24 20:51 |
6-K
|
English | 65.9 KB | ||
| 2024-09-21 00:36 |
Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in co…
|
English | 222.2 KB | ||
| 2024-09-21 00:36 |
Communiqué de presse : Approbation du Sarclisa aux États-Unis : premier anti-CD…
|
French | 255.2 KB | ||
| 2024-09-20 13:45 |
Communiqué de presse : Le CHMP recommande l’approbation du Dupixent dans l’UE p…
|
French | 235.1 KB | ||
| 2024-09-20 13:45 |
Press Release: Dupixent recommended for EU approval by the CHMP to treat eosino…
|
English | 210.9 KB | ||
| 2024-09-20 11:30 |
Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confir…
|
English | 173.2 KB |
Automate Your Workflow. Get a real-time feed of all Sanofi filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Sanofi
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Sanofi via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-05-02 | N/A | Other | Buy | 71,423 | N/A |
| 2024-04-26 | N/A | Other | Buy | 1,000 | 91,380.00 EUR |
| 2023-06-09 | N/A | Other | Buy | 9 | 856.04 EUR |
| 2023-05-02 | N/A | Other | Buy | 65,205 | 6,364,008.00 EUR |
| 2023-05-02 | N/A | Other | Buy | 500 | 48,835.00 EUR |
Peer Companies
